Benjamin H. Lowentritt, MD, FACS, Discusses How 18F-rhPSMA-7.3 PET Expands the Armamentarium for Suspected Recurrent Prostate Cancer

Video

Novel PSMA-targeting PET ligand 18F-rhPSMA-7.3 adds to the recurrent prostate cancer armamentarium, according to Benjamin H. Lowentritt, MD, FACS.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, director of Minimally Invasive Surgery and Robotics; director of the Prostate Cancer Care Program, Chesapeake Urology, Baltimore, Maryland; and president of the American Urological Association, MidAtlantic Region, spoke with CancerNetwork® about how an analysis of the phase 3 SPOTLIGHT study (NCT04186845), assessing 18F-rhPSMA-7.3 in subgroups of patients with suspected recurrent prostate cancer, adds to the existing diagnostic tools for this patient population.

Transcript:

The great part about the SPOTLIGHT study is that it’s adding to the armamentarium that we have for diagnosis and eventually treatment of prostate cancer. [18F-rhPSMA-7.3] is an agent that seems to have the potential for less bladder uptake; it’s a little bit less excreted in the urine and accumulates less in the bladder. The hope would be that it would allow for a very clear picture within the bladder when there’s something to be found there. It continues to add to the options that we have and the hope that this will be available clinically in the future. It’s very promising to have more and more options.

Reference

Lowentritt, B. Impact of Clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Related Videos
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Related Content